Abu Dhabi Sleep Apnea (ADSA) Study

• Conditions: Sleep Apnoea
• Interventions: Other: Questionnaire

• Registration Number: NCT02403141
• Lead Sponsor: Imperial College London Diabetes Centre

Brief Summary

Obstructive sleep apnoea (OSA) is a common medical problem which, despite increasing awareness, remains under-diagnosed. There is a close association between OSA and obesity; 60-70% of patients diagnosed with OSA are either obese or overweight \[1\]. OSA is also very common among patients with type 2 diabetes. Type 2 Diabetes Mellitus (T2DM) has reached epidemic status in the Gulf region. OSA worsens insulin resistance and leads to weight gain through sleep disturbance \[2\]. Several mechanisms have been proposed for the associations of OSA with diabetes and obesity \[3\]. At present there is little available information regarding the prevalence of OSA in the UAE, the relationship with T2DM and obesity, and the impact of OSA on health outcomes in the Emirati population. This research will explore these relationships and inform public health decisions regarding diagnostic pathways, service provision and treatment protocols.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-03
• Study First Submitted: 2015-03-25
• Study First Submitted QC: 2015-03-30
• Study First Posted: 2015-03-31
• Status Verified: 2017-03
• Primary Completion: 2017-03
• Study Completion: 2017-03
• Last Update Submitted: 2017-03-01
• Last Update Posted: 2017-03-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1400

Inclusion Criteria

Participants aged between 18-64 years old. Both Gender male and female.

Exclusion Criteria

Paediatrics below the age of 18. Any participant who is unable to take part

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Impaired fasting glycaemia	Questionnaire	Patients with blood glucose between 5.6mmol/L - 7mmol/L
Type 1 diabetes	Questionnaire	Patients on insulin and with positive IA2 and/or GAD antibodies.
Normal glucose tolerance	Questionnaire	Patients with normal fasting glucose. Blood glucose less than 5.6mmol/L
Type 2 diabetes	Questionnaire	Patients with blood glucose higher than 7mmol/L and negative IA2 and GAD antibodies.

Primary Outcome Measures

Name	Time	Method
Primary objective (Establishing the prevalence of OSA in the study population.)	3 months	Establishing the prevalence of OSA in the study population.

Trial Locations

Locations (1)

Imperial College London Diabetes Centre; 🇦🇪 Abu Dhabi, United Arab Emirates